ASX Growth Companies With High Insider Ownership For February 2025

In This Article:

As the Australian market braces for the Reserve Bank's first interest rate decision of the year, investor sentiment remains cautious, with ASX 200 futures pointing to a lower open amid global economic uncertainties. In such a climate, growth companies with high insider ownership can offer a unique appeal; they often signal confidence from those closest to the business and may provide resilience against broader market fluctuations.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Clinuvel Pharmaceuticals (ASX:CUV)

10.4%

26.2%

SKS Technologies Group (ASX:SKS)

29.7%

24.8%

Medallion Metals (ASX:MM8)

13.8%

67.5%

Acrux (ASX:ACR)

14.6%

91.8%

Emerald Resources (ASX:EMR)

18.1%

34.7%

Newfield Resources (ASX:NWF)

31.5%

72.1%

AVA Risk Group (ASX:AVA)

15.8%

77.3%

Pointerra (ASX:3DP)

23.8%

126.4%

Plenti Group (ASX:PLT)

12.7%

120.1%

Findi (ASX:FND)

35.8%

111.4%

Click here to see the full list of 95 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Aurelia Metals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$405.98 million.

Operations: The company's revenue is derived from its operations at the Peak Mine (A$207.34 million), Dargues Mine (A$102.36 million), and Hera Mine (A$0.20 million).

Insider Ownership: 23.2%

Revenue Growth Forecast: 10.6% p.a.

Aurelia Metals is trading significantly below its estimated fair value, suggesting potential undervaluation. The company is expected to achieve profitability within three years, with revenue growth projected at 10.6% annually, outpacing the Australian market average of 5.9%. Despite a low forecasted return on equity of 9.6%, insider ownership remains a positive indicator for alignment with shareholder interests. Upcoming Q2 2025 earnings results on January 29 may provide further insights into its financial trajectory.

ASX:AMI Earnings and Revenue Growth as at Feb 2025
ASX:AMI Earnings and Revenue Growth as at Feb 2025

PolyNovo

Simply Wall St Growth Rating: ★★★★★☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.32 billion.

Operations: The company generates revenue of A$103.23 million from the development, manufacturing, and commercialization of the NovoSorb technology.